10-Q: Serina Therapeutics Reports Q1 2025 Results, Cites Going Concern Uncertainty

Serina Therapeutics reports a net loss of $4.8 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern.

Summary

• Serina Therapeutics, a clinical-stage biotechnology company, announced its financial results for the quarter ended March 31, 2025.
• The company reported a net loss of $4.8 million, or $0.49 per share, compared to a net loss of $15.0 million, or $5.38 per share, for the same period in 2024.
• Research and development expenses increased to $3.0 million from $1.1 million year-over-year, driven by increased personnel costs and outside research services.
• General and administrative expenses also rose to $2.9 million from $1.2 million in the prior year, due to increased salaries, stock-based compensation, and consulting expenses.
• The company's cash and cash equivalents stood at $4.3 million as of March 31, 2025.
• Management expresses substantial doubt about the company's ability to continue as a going concern, citing recurring losses and the need for additional financing.
• Subsequent to the quarter, on April 8, 2025, Serina Therapeutics entered into a Securities Purchase Agreement, raising approximately $5.0 million through a private placement of Series A convertible preferred stock.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the reported net loss, the going concern warning, and the identified material weaknesses in internal controls. However, the subsequent capital raise provides a slight positive offset.

Positives

• Net loss decreased from $15.0 million in Q1 2024 to $4.8 million in Q1 2025.
• The company secured $5.0 million in funding through a private placement subsequent to the quarter's end.

Negatives

• The company reported a net loss of $4.8 million for Q1 2025.
• Management expresses substantial doubt about the company's ability to continue as a going concern.
• The company's disclosure controls and procedures were not effective as of March 31, 2025, due to material weaknesses.

Risks

• The company's ability to continue as a going concern is uncertain due to recurring losses and the need for additional financing.
• The company's disclosure controls and procedures were not effective as of March 31, 2025, due to material weaknesses.
• The company faces risks common to early-stage biotechnology companies, including technical risks, competition, dependence on key personnel, and regulatory compliance.
• The company may be unable to raise additional funds or enter into collaborations on favorable terms.

Future Outlook

The company expects to incur substantial expenditures in the foreseeable future for the development of its product candidates and will require additional financing to continue this development.

Management Comments

• Management believes that its cash and cash equivalents of $4.3 million as of March 31, 2025, along with the $5.0 million of cash proceeds received in April 2025 from a Securities Purchase Agreement entered with certain investors for a private placement of securities, will be used to fund Company operations but are not expected to be sufficient to satisfy the Companys anticipated operating and other funding requirements for the twelve months from the issuance of these condensed consolidated interim financial statements.

Industry Context

Serina Therapeutics is operating in the competitive biotechnology industry, focusing on developing drug product candidates for neurological diseases and pain using its POZ drug delivery technology.

Comparison to Industry Standards

• It is difficult to compare Serina Therapeutics directly to industry standards without more specific information on comparable companies and projects.
• However, early-stage biotechnology companies often face similar challenges in securing funding, advancing product candidates through clinical trials, and obtaining regulatory approvals.
• Companies like Biohaven Pharmaceutical (acquired by Pfizer) and Amarin Corporation have faced similar hurdles in developing and commercializing neurological and cardiovascular therapies, respectively.
• Success in the biotechnology industry often depends on factors such as the novelty and efficacy of the technology, the strength of the intellectual property portfolio, and the ability to secure partnerships and funding.

Related Party Transactions

• On December 23, 2024, the Company entered into the Stock Purchase Agreement with Juvenescence, pursuant to which Juvenescence purchased all of the outstanding shares of UniverXome.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees face uncertainty due to the company's financial situation.
• Customers (potential patients) may experience delays in the development of new therapies.
• Suppliers and creditors face increased risk of non-payment.

Next Steps

• Advance lead product candidate, SER 252 into Phase I clinical trials.
• Advance other product candidates.
• Advance preclinical programs to clinical trials.
• Further invest in pipeline.
• Seek regulatory approval for investigational medicines.
• Maintain, expand, protect, and defend intellectual property portfolio.
• Secure facilities to support continued growth in research, development, and commercialization efforts.
• Increase headcount to support development efforts and to expand clinical development team.

Key Dates

Keywords

Serina Therapeutics, financial results, Q1 2025, net loss, research and development, going concern, biotechnology, pharmaceuticals, POZ technology, clinical stage